Treatments for chronic myeloid leukemia: a qualitative systematic review

BACKGROUND: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for patients with chronic-phase CML, and its introduction was associated with substantial improvements in response and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferdinand, Roxanne, Mitchell, Stephen A, Batson, Sarah, Tumur, Indra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419508/
https://www.ncbi.nlm.nih.gov/pubmed/22915985
http://dx.doi.org/10.2147/JBM.S33380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419508/
https://www.ncbi.nlm.nih.gov/pubmed/22915985
http://dx.doi.org/10.2147/JBM.S33380

Ejemplares similares